Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Methanesulfonamide Group: Bright and Dark Sides of hERG Potassium Channel Inhibition.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium.

Basic research in cardiology·2026
Same author

Targeting Arrhythmogenic Late Sodium Current by FHF1<sub>A</sub>-Derivative FixR in Heart Failure Cardiomyocytes.

Circulation research·2026
Same author

Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression.

Basic research in cardiology·2026
Same author

A small molecule voltage-sensor modulator enhances the function of the cardiac Na<sub>V</sub>1.5 channel.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Excitation-contraction coupling, cardiomyocyte electrophysiology, and transcriptome profiles in two HFpEF murine models: etiology and sex-dependent differences.

American journal of physiology. Heart and circulatory physiology·2025

Related Experiment Video

Updated: Apr 21, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

16.8K

Class IV antiarrhythmic agents: new compounds using an old strategy.

Norbert Szentandrássy, Dénes Nagy, Bence Hegyi

  • 1Department of Physiology, University of Debrecen, Nagyerdei krt. 98. H-4012 Debrecen, Hungary. szentandrassy.norbert@med.unideb.hu.

Current Pharmaceutical Design
|October 30, 2014
PubMed
Summary

Calcium channel antagonists (CCAs) treat cardiac arrhythmias by blocking L- and T-type calcium channels. Phenylalkylamines and benzothiazepines are key CCAs for antiarrhythmic therapy, with newer drugs also showing potential.

More Related Videos

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

7.8K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

3.6K

Related Experiment Videos

Last Updated: Apr 21, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

16.8K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

7.8K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

3.6K

Area of Science:

  • Cardiology and Pharmacology
  • Focuses on cardiovascular system and drug mechanisms

Background:

  • Cardiac arrhythmias are a significant cause of illness and death.
  • Calcium channel antagonists (CCAs) are established treatments for various cardiovascular conditions, including arrhythmias, hypertension, and angina.
  • L- and T-type calcium channels play crucial roles in cardiovascular function.

Purpose of the Study:

  • To review the role of calcium channel antagonism in treating cardiac arrhythmias.
  • To focus on phenylalkylamines, benzothiazepines, and novel antiarrhythmic drugs.
  • To explore the mechanisms underlying the antiarrhythmic effects of CCAs.

Main Methods:

  • Literature review of existing studies and clinical practices.
  • Analysis of the pharmacological actions of different CCA classes.
  • Examination of the physiological roles of L- and T-type calcium channels.

Main Results:

  • Dihydropyridines are effective vasodilators and antianginal agents but not typically used for arrhythmias.
  • Phenylalkylamines and benzothiazepines demonstrate significant cardiac actions, making them suitable antiarrhythmic choices.
  • Newer compounds are emerging with potential antiarrhythmic properties.

Conclusions:

  • CCAs, particularly phenylalkylamines and benzothiazepines, are vital in managing cardiac arrhythmias.
  • Understanding calcium channel antagonism mechanisms is key to developing new antiarrhythmic therapies.
  • Further research into novel CCAs holds promise for improved cardiac arrhythmia treatment.